Articles

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

Center of Cellular Therapy “G. Lanzani”, Division of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Genmab, Utrecht, the Netherlands
Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA
Genmab, Utrecht, the Netherlands
Center of Cellular Therapy “G. Lanzani”, Division of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Center of Cellular Therapy “G. Lanzani”, Division of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Center of Cellular Therapy “G. Lanzani”, Division of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Genmab, Utrecht, the Netherlands;Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
Genmab, Utrecht, the Netherlands
Center of Cellular Therapy “G. Lanzani”, Division of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Vol. 100 No. 1 (2015): January, 2015 https://doi.org/10.3324/haematol.2014.107011